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Summary. High-dose cytarabine is currently used in
combination with anthracycline in the treatment of acute
myeloblastic leukaemia (AML). Moreover, high-dose cytar-
abine has been reported to produce long-term disease-free
survival in a proportion of patients, especially in certain
subtypes of AML. However, it remains unknown whether
the outcome of patients undergoing allogeneic or auto-
logous stem cell transplantation is influenced by previous
treatment with high-dose cytarabine. To this end, 1672
patients with AML in first remission who were reported to
the Acute Leukaemia Working Party registry of the
European Group for Blood and Marrow Transplantation
(EBMT) and who were transplanted between 1980 and 1995
were analysed according to the dose intensity of cytarabine
given at induction and/or consolidation. Autologous stem
cell transplantation (ABMT) was performed in 846 patients
and allogeneic bone marrow transplantation (BMT) in 826
patients. This study shows that the dose of cytarabine (Ara-
C) given at induction and/or consolidation did not influence
the relapse incidence in patients subsequently allografted or
autografted. In addition, it did not give any advantage in
terms of overall outcome. Therefore, high-dose (HD) Ara-C
may not be needed for patients who have a planned stem
cell transplantation (SCT) as post-remission therapy. Never-
theless, HD Ara-C may be utilized in certain subtypes of
AML that are believed to be curable by chemotherapy alone.
Keywords: cytarabine, bone marrow transplantation, acute
myeloblastic leukaemia.
High-dose cytarabine (HD Ara-C) has been shown to be
effective for both the induction and consolidation of
complete remission (CR) in patients with acute myeloblastic
leukaemia (AML) (Mayer et al, 1994; Mitus et al, 1995;
Bishop et al, 1996; Weick et al, 1996; Cole & Gibson, 1997;
Fopp et al, 1997; Rowe & Tallman, 1997). In patients below
60 years of age who were treated using chemotherapy alone
without transplant, a randomized study of various doses of
Ara-C administered for consolidation has shown that, in
younger patients, the higher the dose of Ara-C the better the
outcome. In the South-West Oncology Group±Eastern Co-
operative Oncology Group±Cancer and Leukaemia Study
Group B (SWOG±ECOG±CALGB) (Cassileth et al, 1998)
intergroup randomized study that compared conventional
chemotherapy using HD Ara-C with allogeneic (BMT) and
autologous (ABMT) stem cell transplantations, consolida-
tion with HD Ara-C led to a better outcome than the
transplantations. This was as a result of salvage by
autologous or allogeneic bone marrow transplantation in
the patients who relapsed after HD Ara-C. Although both
HD Ara-C and stem cell transplantation are effective
therapeutic measures for curing AML, it is unknown
whether the combination of the two, i.e. HD Ara-C in the
pre-transplant period followed by transplant, would be of
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benefit or would increase toxicity. To answer the question,
we retrospectively analysed results from transplants
reported to the registry of the Acute Leukaemia Working
Party of the European Co-operative Group for Blood and
Marrow Transplantation (EBMT).
PATIENTS AND METHODS
Patients. The study included 1672 patients with AML in
first complete remission (CR1). These patients were trans-
planted between 1980 and 1995 and were reported to
the Acute Leukaemia Working Party of the EBMT. Eight
hundred and forty-six were transplanted with autologous
stem cells and 826 with BMT from an HLA-matched sibling.
Patients and transplant characteristics are given in Table I.
The dose intensity of Ara-C was defined as follows: standard
dose (SD) for patients receiving 100±200 mg/m2/d for 5±10 d,
high dose (HD) for patients receiving 1´5±3 g/m2/d for 4±6 d.
Patients receiving doses falling between these two groups were
included in an intermediate group (ID). Following these
criteria, 820 patients among the autologous group received
Ara-C for induction and 803 patients received Ara-C for post-
remission therapy. For induction, 767 patients received SD
and 31 patients received HD. For post-remission therapy, 358
patients and 284 patients received SD and HD respectively.
Among the BMT group, 809 patients received Ara-C for
induction and 670 patients received Ara-C for post-remission
treatment. During induction, 733 patients were treated with
SD and 45 patients with HD. For post-remission therapy, 393
patients received SD and 201 patients received HD.
Statistical methods. Data were analysed from December
1998. All analyses were performed using the SPSS
statistical package software. Leukaemia-free survival (LFS),
relapse incidence (RI) and transplant-related mortality
Table I. Patient characteristics.
Autograft Allograft
Induction
No 26 17
LD 2 5
SD 767 733
ID 20 26
HD 31 45
Consolidation
No 43 156
LD 3 8
SD 358 393
ID 158 68
HD 284 201
Induction and/or consolidation
No 3 6
LD 2 3
SD 351 493
ID 174 89
HD 301 230
Median age (range) 35 years (, 1±69) 29 years (, 1±53)
Year of SCT (median) 1991 (80±95) 1990 (80±95)
Delay diagnosis to CR1 39 d (10±921) 42 d (15±491)
Delay CR1 to SCT 129 d (10±1245) 92 d (10±554)
Sex, male/female 430/416 435/390
Purge, yes/no 172/674 ±
TBI, yes/no 355/381 521/132
FAB, M1/M2/M3/M4/M5/M6/M7 147/230/109/184/126/15/9 132/259/94/195/80/20/7
WBC ( 109/l), median (range) 13´8 (0´3±474) 11´7 (0´2±336)
Donor age 27 (, 1±57)
Donor sex, male/female 425/359
GVHD prevention CSA/MTX/both/T-cell depletion 72/69/298/167
aGVH, yes/no 426/262
aGVHD score (I/II/III/IV) 138/134/43/47
Delay SCT to aGVHD 21 d (3±92)
cGVHD, yes/no 306/322
No, no Ara-C; LD, low-dose Ara-C; SD, standard-dose Ara-C; ID, intermediate dose Ara-C; HD, high-dose Ara-C; SCT, stem cell
transplantation; CR1, first complete remission; TBI, total body irradiation; WBC, white blood cells at diagnosis; GVHD, graft-
versus-host disease; CSA, cyclosporin A; MTX, methotrexate; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-
versus-host disease.
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(TRM) were calculated using the Kaplan±Meier product
limit method.
Comparison of these data was based on results from log
rank tests. The Cox regression model was applied to assess
the prognostic value of both patient and treatment
characteristics in relation to relapse, LFS and TRM. Variables
tested with the doses of Ara-C were age, gender, white blood
cell count (WBC) at diagnosis, French±American±British
(FAB) classification, cytogenetics, interval between diagnosis
and CR, interval between diagnosis and BMT, conditioning
Table II. Autografts: 5-year results in relation to the dose of Ara-C at induction and/or consolidation.
Dose Ara-C Patients
LFS
(means ^ SE)
RI
(means ^ SE)
TRM
(means ^ SE)
Induction
No 26 38 ^ 10 56 ^ 10 12 ^ 6
SD 765 46 ^ 2 47 ^ 2 12 ^ 1
ID 20 50 ^ 11 30 ^ 11 27 ^ 10
HD 31 44 ^ 9 47 ^ 9 17 ^ 8
P-value 0´76 0´77 0´2
Consolidation
No 43 36 ^ 8 55 ^ 8 21 ^ 9
SD 357 46 ^ 3 47 ^ 3 13 ^ 2
ID 158 50 ^ 4 47 ^ 4 6 ^ 2
HD 283 46 ^ 3 47 ^ 3 14 ^ 3
P-value 0´63 0´91 0´39
Induction and/or consolidation
SD 44 ^ 3 49 ^ 3 22 ^ 2
ID 51 ^ 4 44 ^ 4 9 ^ 2
HD 46 ^ 3 46 ^ 3 14 ^ 3
P-value 0´65 0´67 0´85
LFS, leukaemia-free survival; RI, relapse incidence; TRM, transplant-related mortality; SE, standard error of the
mean; No, no Ara-C; SD, standard dose Ara-C; ID, intermediate dose Ara-C; HD, high-dose Ara-C.
Table III. Allografts: 5-year results in relation to the dose of Ara-C at induction and/or consolidation.
Dose Ara-C Patients
LFS
(means ^ SE)
RI
(means ^ SE)
TRM
(means ^ SE)
Induction
No 17 76 ^ 10 13 ^ 8 13 ^ 8
SD 726 55 ^ 2 23 ^ 2 28 ^ 2
ID 24 50 ^ 10 21 ^ 9 47 ^ 11
HD 44 45 ^ 8 42 ^ 9 21 ^ 7
P-value 0´14 0´02* 0´98
Consolidation
No 154 51 ^ 4 27 ^ 4 29 ^ 4
SD 393 56 ^ 3 24 ^ 3 26 ^ 3
ID 68 54 ^ 6 21 ^ 6 28 ^ 6
HD 193 56 ^ 4 23 ^ 4 27 ^ 3
P-value 0´88 0´72 0´92
Induction and/or consolidation
SD 493 55 ^ 2 24 ^ 2 27 ^ 2
ID 87 51 ^ 6 22 ^ 5 34 ^ 6
HD 222 55 ^ 3 26 ^ 3 25 ^ 3
P-value 0´72 0´41 0´81
* Among the 45 patients having received HD at induction 16 received HD Ara-C twice and the delay between
diagnosis and CR1 was prolonged in this restricted population (median, 61 d vs. 42 d for the remaining patients).
LFS, leukaemia-free survival; RI, relapse incidence; TRM, transplant-related mortality; SE, standard error of the
mean; No, no Ara-C; SD, standard-dose Ara-C; ID, intermediate-dose Ara-C; HD, high-dose Ara-C.
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regimen, bone marrow purging, source of stem cells, graft-
versus-host disease (GVHD) prophylaxis, acute and/or
chronic GVHD and the year of transplantation. The
characteristics of the three groups of patients who received
standard dose (SD), intermediate dose (ID) or HD Ara-C were
compared using the x2 test for qualitative variables and the
Kruskall±Wallis test for continuous variables. All variables
that were associated with outcome and that showed a
P-value less than 0´2 and/or that had a different
distribution between groups were included in the Cox
model.
RESULTS
Outcome of autografted patients
For ABMT, the dose intensity of Ara-C, whether evaluated at
induction or after remission, did not influence LFS, RI or
TRM at 5 years (Table II).
Outcome of allografted patients
After BMT, relapse incidence was more important for
patients induced with HD Ara-C than for patients induced
with SD Ara-C. There was no statistical difference between
TRM and LFS. No difference was found among the three
groups of Ara-C prescribed as post-remission therapy in
terms of probability of LFS, RI or TRM at 5 years (Table III).
Prognostic factors other than dose of Ara-C: univariate analysis
In the ABMT patients, age, date of transplant, FAB M3,
purging and interval between diagnosis and remission all
had a prognostic value for relapse and LFS.
In the BMT patients, age, interval between diagnosis and
Table IV. (A) Cytogenetics at diagnosis.
Autografts: patient distribution
Good(n = 49) t(15;17), t(8;21), inv(16)
Poor (n = 23) abn 5 and/or 7, hypodiploidy, abn 11q
Standard (n = 140) All others
Allografts: patient distribution
Good(n = 53) t(15;17), t(8;21), inv(16)
Poor (n = 20) abn 5 and/or 7, hypodiploidy, abn 11q
Standard (n = 139) All others
(B) Dose of Ara-C at induction and/or consolidation by cytogenetic group.
SD (%) ID (%) HD (%)
Autografts
Good 25 (22) 5 (22) 18 (24)
Standard 75 (69) 16 (70) 46 (61)
Poor 9 (8) 2 (9) 11 (15)
Allografts
Good 33 (27) 10 (33) 10 (18)
Standard 77 (62) 19 (63) 42 (75)
Poor 14 (11) 1 (3) 4 (7)
(C) Outcome (5 years) according to cytogenetic cytostratification
LFS
(means ^ SE)
RI
(means ^ SE)
TRM
(means ^ SE)
Autografts
Cyto good 46 ^ 7 46 ^ 7 15 ^ 6
Cyto standard 46 ^ 4 49 ^ 5 10 ^ 3
Cyto poor 26 ^ 9 73 ^ 9 4 ^ 4
P-value 0´15 0´05 0´74
Allografts
Cyto good 62 ^ 7 12 ^ 5 29 ^ 6
Cyto standard 58 ^ 4 24 ^ 4 24 ^ 4
Cyto poor 27 ^ 11 62 ^ 14 24 ^ 4
P-value 0´02 0´0004 0´93
SD, standard dose Ara-C; ID, intermediate dose Ara-C; HD, high-dose Ara-C; LFS, leukaemia-
free survival; RI, relapse incidence; TRM, transplant-related mortality; SE, standard error of the
mean.
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CR1, WBC at diagnosis and T-cell depletion influenced LFS.
WBC at diagnosis, T-cell depletion and cytogenetics
influenced relapse. TRM was influenced by age, year of
transplant, total body irradiation (TBI) and interval between
diagnosis and CR1.
Acute GVHD was associated with a lower relapse
incidence, a higher TRM and a lower LFS. Chronic GVHD
was not analysed owing to a lack of data.
Results of cytogenetics were available for 425 patients.
Table IVA shows the distribution of patients within the good,
standard and poor risk categories according to the modified
Chicago classification. The distribution of the cytogenetic
categories in relation to the dose of Ara-C did not show any
unbalance (Table IVB). As previously shown by the EBMT
(Ferrant et al, 1997), the outcome after either autografting
or allografting was worse in the poor risk category patients
(Table IVC). The distribution of the cytogenetic subgroups
was identical between the three doses of Ara-C, but it was
not possible to include cytogenetics in the multivariate
analysis owing to the small number of patients in each
subgroup.
Prognostic factors: multivariate analysis
Variables differing significantly or recognized as potential
prognostic factors were included as covariates in the
multivariate analysis. The dose of Ara-C given at induction
or after remission had no influence on the outcome of
ABMT in terms of LFS, RI or TRM. Other independent
Table V. Autografts: multivariate analysis.
Covariate P-value RR 95% CI
LFS Interval diagnosis to CR1 . 39 d 0´04 1´25 1´02±1´55
Adult 0´0035 1´60 1´17±2´2
Year SCT . 1987 0´014 0´71 0´54±0´93
M3 FAB 0´03 0´66 0´46±0´95
RI Interval diagnosis to CR1 . 39 d 0´033 1´29 1´02±1´62
Adult 0´03 1´46 1´05±2´02
Year SCT . 1987 0´004 0´66 0´49±0´9
M3 FAB 0´005 0´54 0,36±0,83
TRM Adult 0´03 3´65 1´13±11´7
Covariates: Ara-C at induction and/or consolidation, SD vs. ID vs. HD; age, children vs.
adults; Year of SCT, # 1987 vs. . 1987; purge, yes vs. no; FAB, M3 vs. M5 vs. other;
interval diagnosis to CR1, # 39 d vs. . 39 d (median).
SCT, stem cell transplantation; CR1, first complete remission; RR, relative risk; CI,
confidence interval.
Table VI. Allografts: multivariate analysis.
Covariate P-value RR 95% CI
LFS Interval diagnosis to CR1 . 42 d 0´034 1´50 1´03±2´17
T depletion 0´01 1´63 1´12±2´39
RI Interval diagnosis to CR1 . 42 d 0´02 1´99 1´11±3´59
No TBI 0´008 2´56 1´26±5
WBC . 11´7 ( 109/l) 0´03 1´93 1´07±3´5
T depletion 0´007 2´37 1´27±4´43
No aGVHD 0´014 2´13 1´16±3´84
TRM Adult 0´03 3´70 1´15±12
aGVHD 0´0002 3´21 1´75±5´9
Covariates: Ara-C at induction and/or consolidation, SD vs. ID vs. HD; age, children vs.
adults; age donor, children vs. adults; year of SCT, # 1987 vs. . 1987; TBI, yes vs. no; FAB,
M3 vs. M5 vs. other; interval diagnosis to CR1, # 42 d vs. . 42 d (median); WBC at
diagnosis, # 11´7 vs. . 11´7 ( 109/l); T depletion; aGVHD (time-dependent covariate). SCT,
stem cell transplantation; TBI, total body irradiation; CR1, first complete remission; WBC,
white blood cell at diagnosis; aGVHD, acute graft-versus-host disease; LFS, leukaemia-free
survival; RI, relapse incidence; TRM, transplant-related mortality; RR, relative risk; CI,
confidence interval.
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factors are shown in Table V. In the BMT patients, no
influence of SD or HD Ara-C (Table VI) was observed.
DISCUSSION
Uncertainty remains about optimal remission and post-
remission Ara-C regimens for de novo AML outside the
context of stem cell transplantation (SCT). Although pilot
studies suggested a significant improvement with higher
doses, there have been only two prospective randomized
trials using HD Ara-C as part of the standard induction. In
the SWOG study (Weick et al, 1996), patients were
randomized for induction between SD or HD Ara-C and
both groups received daunorubicin (DNR). Complete
responders to HD Ara-C received an additional course of
HD Ara-C and DNR. Complete responders to SD were
randomized to receive SD plus DNR or HD plus DNR.There
was no advantage for HD Ara-C in terms of CR rates. The
LFS was better in patients treated with HD Ara-C, but was
associated with significantly more lethal toxicities. Similar
findings were reported by the Australian Leukaemia Study
Group (Bishop et al, 1996) in a study that compared HD
Ara-C plus daunorubicin and etoposide with SD Ara-C plus
daunorubicin and etoposide. Patients in CR tended to
survive longer with HD Ara-C, but there was no statistical
difference between the two arms in terms of overall survival.
More frequently, schedules including HD Ara-C have been
included as post-remission intensification therapy. The
Cancer and Leukaemia Study Group B (CALGB) (Mayer
et al, 1994) randomized patients in remission between three
groups in order to compare the dose intensity of Ara-C. The
three different groups received 6 g/m2/d at days 1, 3 and 5,
400 mg/m2/d for 5 d and 100 mg/m2/d for 5 d respec-
tively. At 4 years, the disease-free survival rate (DFS) was
significantly in favour of the higher dose in patients less
than 60 years of age. The patients also experienced
significant dose-related toxicities. The Swiss Group for
Clinical Cancer Research (Fopp et al, 1997) has recently
published results suggesting that Ara-C dose intensity might
be more important than the total cumulative dosage. The
question of the type of chemotherapy given before SCT has
never been analysed in terms of dose intensity. Several
studies have investigated the optimal interval between CR1
and SCT. This approach has always been limited by biases
such as relapse with time, complications that delay
transplant or poor haematological recovery for autologous
stem cell harvest (Gorin, 1998). The best chemotherapy
regimen available is not necessarily the best option before
transplantation. More frequently now, BMT is performed
quickly after achieving CR1, whereas the therapies between
CR1 and ABMT are quite heterogeneous in length and
intensity. In some studies, ABMT can be considered as an
additional treatment, whereas in others it takes the place of
another intensification.These could be the major explana-
tions for the differences observed between randomized trials
(Zittoun et al, 1995; Reiffers et al, 1996; Harousseau et al,
1997; Burnett et al, 1998; Cassileth et al, 1998) showing
various differences between chemotherapy and ABMT
according to different designs and timing of transplantation.
Apart from the dose of Ara-C, the type and dose of
anthracycline used, both in induction and after remission,
may be important, especially when considering idarubicin.
From the data reported here, we can speculate that high-
dose therapy administered with SCT could abrogate the
advantage of previous intermediate or HD Ara-C.
HD Ara-C improves LFS in chemotherapy-treated AML
patients despite higher toxicity, including Ara-C-related
mortality. Patients who died as a result of Ara-C toxicity
could not proceed to BMT and therefore the present study
has focused on a selected group of patients that should have
favoured the appearance of a possible beneficial effect of
Ara-C after BMT. However, no such effect was found.
Because in vivo purging with HD Ara-C has been used in
several trials (Zittoun et al, 1995; Harousseau et al, 1997;
Schiller et al, 1997; Burnett et al, 1998; Pavlovsky et al,
1998) and has a major disadvantage in prolonging the
delay to platelet recovery, its use before ABMT should be
avoided. Presently, the choice between conventional che-
motherapy and BMT is being approached in a different way,
according to the prognostic factors at diagnosis, such as
cytogenetics (Ferrant et al, 1997; Bloomfield et al, 1998;
Grimwade et al, 1998). Some current trials are now
stratifying treatment approach by using cytogenetics and
by considering HD Ara-C as the option of choice for core
binding factor-type cytogenetic abnormalities in adult AML
with BMT being reserved for relapse. However, we did not
analyse patients with inv(16) and t(8;21) at diagnosis
separately because of their low number and also to avoid the
statistical problems associated with subgroup analysis.
In conclusion, to analyse the impact of HD Ara-C given at
induction or post-remission therapy before subsequent
intensification with SCT, we have retrospectively studied
data reported to the EBMT. Three subgroups have been
compared. This study clearly shows that increasing the dose
of Ara-C before SCT does not give any advantage in terms of
outcome. HD Ara-C does not seem to be the gold standard
before BMT or ABMT and probably should be dedicated to
certain subtypes of AML that can be treated using
chemotherapy alone.
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